日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Dabogratinib (TYRA-300), an FGFR3 Isoform-Selective Inhibitor: Preclinical and Initial Clinical Evidence of Antitumor Activity

Dabogratinib (TYRA-300),一种FGFR3亚型选择性抑制剂:抗肿瘤活性的临床前和初步临床证据

Starrett, Jacqueline H; Allen, Eric L; Neal, Melissa; Iyer, Samhita; Ye, Qing; Hudkins, Robert L; Degaonkar, Viraj; Lihou, Christine; Swanson, Ronald V; Boni, Valentina; Fuentes-Antrás, Jesús; Pobel, Cedric; Loriot, Yohann; Zalutskaya, Alena; Goluboff, Erik

The future of androgen receptor targeting in prostate cancer: third-generation inhibitors and beyond

前列腺癌雄激素受体靶向治疗的未来:第三代抑制剂及后续疗法

Bernard-Tessier, Alice; Naoun, Natacha; Barraud, Solenn; Flippot, Ronan; Pobel, Cedric; Rey, Macarena; Baldini, Capucine; Massard, Christophe; Patrikidou, Anna; Fuerea, Alina; Di Palma, Mario; Albigès, Laurence; Loriot, Yohann; Fizazi, Karim

Clinical efficacy and safety of a single administration of fluralaner injectable suspension (BRAVECTO(®) injectable) vs. monthly administration of oral afoxolaner (NexGard(®)) in dogs for tick and flea control over one year under European field conditions

在欧洲野外条件下,单次注射氟雷拉纳混悬液(BRAVECTO®注射液)与每月口服阿福拉纳(NexGard®)在犬蜱跳蚤防治中的临床疗效和安全性比较,为期一年。

Petersen, Ivo; Goebel-Lauth, Susanne; Pobel, Thierry; Gil, Maria J; Löhlein, Wolfgang; Wolf, Oliver; Zschiesche, Eva; Welzel, Bjoern; Heinau, Lea

Resistance to Selective FGFR Inhibitors in FGFR-Driven Urothelial Cancer

FGFR驱动的尿路上皮癌对选择性FGFR抑制剂的耐药性

Francesco Facchinetti ,Antoine Hollebecque ,Floriane Braye ,Damien Vasseur ,Yoann Pradat ,Rastislav Bahleda ,Cédric Pobel ,Ludovic Bigot ,Olivier Déas ,Juan David Florez Arango ,Giorgia Guaitoli ,Hayato Mizuta ,David Combarel ,Lambros Tselikas ,Stefan Michiels ,Sergey I Nikolaev ,Jean-Yves Scoazec ,Santiago Ponce-Aix ,Benjamin Besse ,Ken A Olaussen ,Yohann Loriot ,Luc Friboulet

Tumor Microenvironment Features as Predictive Biomarkers of Response to Immune Checkpoint Inhibitors (ICI) in Metastatic Clear Cell Renal Cell Carcinoma (mccRCC)

肿瘤微环境特征作为转移性透明细胞肾细胞癌(mccRCC)免疫检查点抑制剂(ICI)疗效的预测性生物标志物

Simonaggio, Audrey; Epaillard, Nicolas; Pobel, Cédric; Moreira, Marco; Oudard, Stéphane; Vano, Yann-Alexandre

Cabazitaxel multiple rechallenges in metastatic castration-resistant prostate cancer

卡巴他赛在转移性去势抵抗性前列腺癌中的多次再治疗

Pobel, Cedric; Auclin, Edouard; Teyssonneau, Diego; Laguerre, Brigitte; Cancel, Mathilde; Boughalem, Elouen; Noel, Johanna; Brachet, Pierre Emmanuel; Maillet, Denis; Barthelemy, Philippe; Helissey, Carole; Thibault, Constance; Oudard, Stéphane

Resistance to cancer immunotherapy in metastatic renal cell carcinoma

转移性肾细胞癌对癌症免疫疗法的耐药性

Moreira, Marco; Pobel, Cedric; Epaillard, Nicolas; Simonaggio, Audrey; Oudard, Stéphane; Vano, Yann-Alexandre

Field effectiveness and safety of fluralaner plus moxidectin (Bravecto® Plus) against ticks and fleas: a European randomized, blinded, multicenter field study in naturally-infested client-owned cats

氟雷拉纳联合莫昔克丁(Bravecto® Plus)对蜱虫和跳蚤的现场有效性和安全性:一项针对自然感染蜱虫和跳蚤的欧洲多中心随机、双盲现场研究

Rohdich, Nadja; Zschiesche, Eva; Wolf, Oliver; Loehlein, Wolfgang; Pobel, Thierry; Gil, Maria José; Roepke, Rainer K A

[Not Available]

[无法使用]

Rausch, Alexander M; Küng, Vera E; Pobel, Christoph; Markl, Matthias; Körner, Carolin

Spatiotemporal variations in microcystin concentrations and in the proportions of microcystin-producing cells in several Microcystis aeruginosa populations

几种铜绿微囊藻种群中微囊藻毒素浓度和产生微囊藻毒素细胞比例的时空变化

M Sabart, D Pobel, E Briand, B Combourieu, M J Salençon, J F Humbert, D Latour